| 摘要: |
| ［摘要］ 膜性肾病是最常见的原发性肾小球疾病之一。疾病特异性靶抗原如M型磷脂酶A2受体（PLA2R）的发现为膜性肾病的诊治开辟新的思路，尤其为针对B细胞谱系的干预提供了基础，即治疗的核心是减少抗体产生和上皮下免疫复合物沉积。该文从膜性肾病的特异性靶抗原出发，探讨有前景的靶向治疗手段。 |
| 关键词: 膜性肾病 靶抗原 B细胞治疗 |
| DOI：10.3969/j.issn.1674-3806.2024.08.01 |
| 分类号:R 692.6 |
| 基金项目:浙江省重点研发计划项目（编号：2020C03034） |
|
| Research progress on target antigens and specific treatment strategies of membranous nephropathy |
|
LU Luying1, HAN Fei2
|
|
1.Department of Nephrology, Shulan(Hangzhou) Hospital, Zhejiang 310004, China; 2.Kidney Disease Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
|
| Abstract: |
| ［Abstract］ Membranous nephropathy is one of the most common primary glomerular diseases. The discovery of disease-specific target antigens such as M-type phospholipase A2 receptor(PLA2R) has opened up new ideas for the diagnosis and treatment of membranous nephropathy, especially providing a basis for the intervention of B-cell lineages. The core of treatment is to reduce antibody production and subepithelial immune complex deposition. This paper explores promising targeted therapy methods starting from the specific target antigens of membranous nephropathy. |
| Key words: Membranous nephropathy Target antigen B-cell therapy |
